CA
NZ
UK
AU
IND
US
Certara, Inc. (NASDAQ: CERT) has announced a significant leadership transition with the exit of President and Chief Commercial Officer Leif E. Pedersen, effective August 1, 2026. Pedersen will serve as a Senior Advisor until December 31, 2026, during which time he will assist in …
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) recorded a net loss of $4.1 million for the second quarter ended June 30, 2026, primarily as a result of reorganizing its financial structure following a $100 million strategic transaction. The substantial move involved Apotex Health acquiring Cumberland's portfolio …
Azenta Inc. reported a weaker-than-expected EPS of $-0.04 for the quarter ending March 31, 2026, missing analyst expectations which forecasted earnings of $0.13. Investors are now reevaluating their positions, particularly as the company faces challenges in returning to profitability. While the miss on earnings …
Azenta (NASDAQ: AZTA) reported third‑quarter revenue of $161 million, a 12% increase from the prior year, while adjusted EBITDA rose to $18 million. The company posted a total diluted EPS of $0.05, outperforming the prior‑year loss of $1.05. The results underscore a strengthening of …
Baxter International Inc. (NYSE: BAX) is preparing to transition its leadership team as Interim Chief Financial Officer Anita Zielinski announced her resignation, effective September 15, 2026. This shift comes against a backdrop of significant stock performance, with shares up 45.4% year-to-date. The timing of …
Beam Therapeutics Inc. (NASDAQ: BEAM) reported a significant net loss of $122.7 million for the second quarter, equating to $1.18 per share. While losses are notable, the company simultaneously initiated a key trial by dosing its first patient in the BEAM-302 study, aiming to …
Bruker Corporation (NASDAQ: BRKR) announced second-quarter 2026 results, reporting $838.5 million in revenue, up 5.2% year-over-year from $797.4 million. This revenue performance comfortably surpassed the consensus estimate, with earnings per share (EPS) of $0.49 exceeding expectations set at $0.39. The results highlight a rebound …
This financing is important for the company as it ramps up efforts to advance its SYNGAP1-related disorder treatment, CMP-002, into clinical trials.
The impressive results came alongside enhancements in profitability metrics, marking a key point for investors who are closely monitoring the company’s recovery trajectory.
Certara, Inc. posted revenue of $93.3 million for the second quarter, reflecting 1% growth from $92.4 million in the same quarter last year. This revenue performance falls short when juxtaposed with the earnings per share (EPS) of $0.08, which did not meet the consensus …
Please wait processing your request...